SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the September 2025 quarter moved down to Rs. 737.21 millions as compared to Rs. 985.46 millions during the year-ago period.The Net Loss for the quarter ended September 2025 is Rs. -244.51 millions as compared to Net Loss of Rs. -385.73 millions of corresponding quarter ended September 2024 Operating profit Margin for the quarter ended September 2025 improved to -55.85% as compared to -177.50% of corresponding quarter ended September 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 737.21 985.46 -25.19 1648.03 1679.18 -1.86 3813.04 4581.81 -16.78
Other Income 10.94 19.82 -44.80 15.81 28.89 -45.28 55.58 55.84 -0.47
PBIDT -55.85 -177.50 -68.54 -160.82 -630.92 -74.51 -606.36 -3.19 18908.15
Interest 84.09 93.37 -9.94 194.58 163.83 18.77 367.07 252.44 45.41
PBDT -139.94 -270.87 -48.34 -355.40 -794.75 -55.28 -973.43 -255.63 280.80
Depreciation 104.57 114.86 -8.96 219.67 207.66 5.78 437.74 363.13 20.55
PBT -244.51 -385.73 -36.61 -575.07 -1002.41 -42.63 -1411.17 -618.76 128.06
TAX 0.00 0.00 0.00 0.00 -219.31 0.00 -63.10 -148.89 -57.62
Deferred Tax 0.00 0.00 0.00 0.00 -219.31 0.00 -63.10 -148.89 -57.62
PAT -244.51 -385.73 -36.61 -575.07 -783.10 -26.56 -1348.07 -469.87 186.90
Equity 222.82 196.11 13.62 222.82 196.11 13.62 196.11 196.09 0.01
PBIDTM(%) -7.58 -18.01 -57.94 -9.76 -37.57 -74.03 -15.90 -0.07 22748.13

Astec Lifesciences Share Price

712.65 -3.00 (-0.42%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
UPL 646.15
PI Industries 3108.10
Bayer CropScience 4608.85
Sharda Cropchem 1121.05
Sumitomo Chemical 485.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×